Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Oct. 31, 2021	Oct. 21, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized	100,000,000	100,000,000		100,000,000		100,000,000
Common stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Fair value of options vested		$ 1.0	$ 0.1
Weighted average grant date fair value		$ 3.50	$ 0.36
Unrecognized stock-based compensation expense		$ 7.9
Unrecognized stock-based compensation expense, weighted-average recognition period		2 years 4 months 24 days
Repurchase of common stock		0	0
Shares subject to repurchase		311,836		377,709
Aggregate exercise prices of early exercised shares		$ 0.2		$ 0.2
Preferred stock, shares authorized	5,000,000	5,000,000		5,000,000		5,000,000
Preferred stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Common stock available for future grants	1,934,095	1,924,967		1,934,095
2021 Plan
Subsidiary or Equity Method Investee [Line Items]
Number of Shares Underlying Outstanding Restricted Stock, Granted	394,750
ESPP
Subsidiary or Equity Method Investee [Line Items]
Common stock available for future grants					401,164
Number of shares authorized for offerings		0
Restricted Stock Units
Subsidiary or Equity Method Investee [Line Items]
Unrecognized stock-based compensation expense		$ 1.4
Unrecognized stock-based compensation expense, weighted-average recognition period		8 months 12 days